|
Sunday, October 21, 2012
|
|
Time
|
Title/Description
|
Comments
|
|
17:30 - 19:30
|
Welcome Reception
Meet with speakers and other attendees at this informal reception in the Sheraton's beautiful Pearl Room.
|
Presented by: BayHelix, BioCentury and Barclays Capital
|
|
Day 1 - Monday, October 22, 2012
|
|
Time
|
Title/Description
|
Speakers
|
|
08:00 - 09:00
|
Registration and Refreshments
|
|
|
09:00 - 09:30
|
Welcome Remarks
|
Greg B. Scott - President & Founder, ChinaBio® LLC
|
|
Yan Lu - Vice Mayor, The People's Government of Taicang City
|
|
09:30 - 10:30
|
Keynote: Health, Healthcare and Healthcare Reform in China
China's healthcare industry is going through tremendous change, much of it driven by government policies including China's $200 billion healthcare reform program and new drug development stimulus. Dr. Cai will cover several topics critical to the industry:
1) Background: Health and Healthcare - current status and issues related to health and healthcare in China;
2) Current Healthcare System in China - the financing and delivery of healthcare in China, including affordability and access to care;
3) Healthcare Reform in China - the current status, the challenges and the trends that will shape the industry's future.
|
John Cai, PhD - Director, Center for Health Care Management and Policy, and Adjunct Professor of Economics, CEIBS
|
|
10:30 - 11:00
|
Networking Break and Refreshments
|
|
|
11:00 - 11:30
|
Plenary 1: Life Science: The Global View
The global life science industry is undergoing rapid change, and many MNCs are rethinking their global commercial and R&D strategies and looking to China to help drive innovation and growth. Dr. Bernstein examines the factors driving change in the pharmaceutical industry and how MNCs are adapting to China's expanding influence in the global market.
|
Karen Bernstein, PhD - Co-Founder and Chairman, BioCentury Publishing
|
|
11:30 - 12:00
|
Plenary 2: China Healthcare: Industry Prognosis
The public markets have been relatively kind to China's healthcare and life science companies, and, according to a recent joint Barclays/ChinaBio study, the sentiment of industry insiders has grown more optimistic about the future. What is driving China's success and will it continue as the global markets struggle to regain their foothold? Dr. Mann will explore possible scenarios for the future, and variables that may influence potential performance.
|
Jason Mann, MD, PhD - Head, China Healthcare Equity Research, Barclays Capital
|
|
12:00 - 12:30
|
Plenary 3: State of China Life Science: From Local to Global
As China's life science industry continues to lead the world in growth, it is quickly evolving from local to global impact. Innovation is now being created inside of China at the same time international companies are bringing innovative products to China. This has stimulated VC investment, M&A and IPO activity in China, and driven partnering and corporate investment to new heights. Mr. Scott will present recent data on the industry, highlighting areas of significant opportunity and risk in China.
|
Greg B. Scott - President & Founder, ChinaBio® LLC
|
|
12:30 - 14:00
|
Luncheon
|
|
|
13:00 - 13:30
|
Luncheon Talk: SFDA Update - Changes for the Better?
It is well recognized that the SFDA can be a deterrent to success in China, but that may be changing. With a change of leadership and the influence of BayHelix and others, the SFDA has begun to make its review structure more transparent and efficient. Many new ideas and approaches have been proposed and some are already in implementation stage. Dr. Zhang will share these changes for the first time in public and discuss their potential impact to companies' R&D and registration strategy in China.
|
Dan Zhang, MD, MPH - Chairman and CEO, Fountain Medical Development Ltd.; Chairman, SFDA Working Committee, BayHelix
|
|
14:00 - 15:30
|
Working Session 1: MNCs in China - Perspectives on Past Success and Future Strategy
Many multinational life science companies have been in China for decades, while others are relatively new. Most have achieved strong or even stellar success here. But with the dramatic shifts in the global landscape, as well as China's ever-changing dynamics, challenges abound, especially for companies looking to enter the China market. This interactive session will examine how MNCs have been successful in China to date, and explore how their strategies are shifting in the new world.
|
Moderator:
David Flores - President and CEO, BioCentury Publishing
|
|
Panelists:
Zheng Li, PhD - General Manager, Lundbeck Research China
|
|
Larry Lin, PhD, MBA - Director, External Scientific Affairs, J&J Janssen Pharmaceutical
|
|
Baoping Wang, PhD - President, Novo Nordisk Research Center China
|
|
Gangfeng Xu, PhD - Divisional VP, Licensing & Acquisitions, China, Abbott Laboratories
|
|
15:30 - 16:00
|
Networking Break and Refreshments
|
|
|
16:00 - 17:30
|
Working Session 2: China's Domestic Pharma - Going Global
China's domestic pharma companies are facing strong market pressures. The government is forcing prices on generics down 20%-30% per year, forcing many companies to develop Western drugs that are more likely to offer margin protection. In addition to creating or expanding their internal R&D groups, many domestic pharma are now seeking to partner with Western companies that provide access to novel technologies. Some companies are also expanding into Western markets, where the approval process and pricing controls can be more favorable. Hear successful China companies describe the methods they are using to become more global, then join the discussion to explore how the focus should change in the future.
|
Moderator:
Jason Mann, MD, PhD - Head, China Healthcare Equity Research, Barclays Capital
|
|
Panelists:
Ming Guo, PhD - Co-Founder & COO, Ascentage Pharma
|
|
Lily Han, PhD - Deputy General Manager of International Department, Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
|
|
Zengquan Wang, PhD - CBO & VP, Viva Biotech Ltd.
|
|
Lianshan Zhang, PhD - President of Global R&D, Jiangsu Hengrui Medicine Co., Ltd.
|
|
17:30 - 18:00
|
Closing Session: Rethinking China - Lessons Learned
A brief analysis and discussion of the days' key information and lessons learned that can be applied to your company's China strategy.
|
Moderator:
Greg B. Scott - President & Founder, ChinaBio® LLC
|
|
Panelists:
Karen Bernstein, PhD - Co-Founder and Chairman, BioCentury Publishing
|
|
David Flores - President and CEO, BioCentury Publishing
|
|
Jason Mann, MD, PhD - Head, China Healthcare Equity Research, Barclays Capital
|
|
Dan Zhang, MD, MPH - Chairman and CEO, Fountain Medical Development Ltd.
|
|
18:30 - 20:30
|
Gala Banquet
|
|
|
Day 2 - Tuesday, October 23, 2012
|
|
Time
|
Title/Description
|
Location
|
|
9:00 - 9:10
|
Tee-off Ceremony
|
East Sea Golf & Country Club
|
|
9:10 - 12:00
|
Golf Outing
All attendees are welcome to play either 9 or 18 holes at East Sea's world class golf course designed by PGA champion Colin Montgomerie, or to join the golf pros for instruction at the driving range.
|
East Sea Golf & Country Club
|
|
12:00 - 14:00
|
Luncheon
|
Clubhouse
|
|
14:00 - 16:00
|
Closing Reception / Award Ceremony
|
Clubhouse
|
